| abstract |
"METHOD OF TREATMENT THROUGH A COMBINATION OF A TISSUE PLASMINOGEN ACTIVATOR VARIANT (t-PA) AND A LOW MOLECULAR WEIGHT HEPARIN AND USE OF THE SAME". The present invention relates to an improved therapeutic regimen for the treatment of thrombolytic dysfunctions, such as acute myocardial infarction (AMI). Particularly, the present invention relates to the treatment of thrombolytic dysfunctions, such as AMI, with a combination of a tissue plasminogen activating variant (t-PA) that has higher fibrin specificity and longer plasma half-life compared to wild-type human t-PA and low molecular weight heparin. |